Research context
A thymic peptide studied in immune function; approval status varies by country.
Regulatory note: Verify local laws, product approval and professional guidance before any human use. This profile is not a recommendation for use.
Immune research
Thymosin Alpha-1
A thymic peptide studied in immune function; approval status varies by country.
53 connected records49 graded citations0 external identifiers
Evidence map
Claims linked to original records.
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Kang X, Wang S, Zhang L, Hu M, Su X, Liu Y, Qin Q, Yi H, Yuan L, Cai W, Wei L, Lu Z
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
pubmed
Chuang SC, Hung PC, Rethi L, Lin YW, Chau HD, Pham VK, Vo AT, Nguyen HT, Tzou KY, Chuang AE
Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.
pubmed
Mishra S, Telang G, Sureshbabu A, Kulkarni S, Barage S, Kumar AWS, Singh R
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro.
pubmed
Wei Y, Chen J, Zhang Y, Liu Y, Zhu F, Wang X, Zhou X, Wu C, Zhang W, Chen J, Zhang Y, Pan N, Chen K, Zheng S, Yan C, Liu L, Wang L
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
pubmed
Mazza AD
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
pubmed 2026
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
pubmed 2026
Li T, Wu BL, Yu CL, Jin LY
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
pubmed 2026
Shyanti RK, Sharma S, Haque M, Tiwari RK, Singh R, Mishra M
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.
pubmed
This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine chemotherapy + anti-PD-1 monoclonal antibody and Thymalfasin for borderline resectable pancreatic cancer, and to...
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
clinicaltrials 2024
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients. The final aim is that of gathering information needed for...
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
clinicaltrials 2009
The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1....
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
clinicaltrials 2016
The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
clinicaltrials 2020
Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to the ICU.
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
clinicaltrials 2022
Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy of a metastatic site in metastatic colorectal...
Abscopal Effect for Metastatic Colorectal Cancer
clinicaltrials 2015
This is a prospective, single-center, randomized controlled, phase II clinical trial. The study aims to enroll 48 patients with resectable, locally advanced gastroesophageal junction adenocarcinoma who have not received any treatment. After obtaining informed consent and meeting the inclusion/exclusion criteria, patients were randomly assigned preoperatively...
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
clinicaltrials 2025
This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the...
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
clinicaltrials 2025
Kim SD, Kim KR, Kim DH, Yeo T, Choi MJ, Park SJ, Yoo HS
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.
pubmed
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib...
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
clinicaltrials 2025
Patients with small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy of a metastatic site in...
Abscopal Effect for Metastatic Small Cell Lung Cancer
clinicaltrials 2015
Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients. 2....
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
clinicaltrials 2015
This is a multicenter, open-label, prospective, randomized controlled Phase II clinical study. All eligible subjects will be randomly assigned in a 1:1 ratio to either the triple therapy group or the double therapy group. Triple therapy group: Subjects will receive Thymalfasin in combination with Regorafenib...
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
clinicaltrials 2025
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Thymosin-α1 for Recurrent Implantation Failure
clinicaltrials 2026
Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
clinicaltrials 2014
The primary objective of this clinical trial is to evaluate the efficacy and safety of spatially fractionated radiotherapy combined with the PraG strategy in the treatment of soft tissue sarcoma (STS). The main questions it aims to answer are: 1. Can spatially fractionated radiotherapy combined...
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
clinicaltrials 2026
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha and interleukin-2. The secondary aim is to investigate whether a measurable...
Dendritic Cell Based Therapy for Breast Cancer Patients
clinicaltrials 2009
Kim SD, Kim KR, Kim DH, Yeo T, Choi MJ, Park SJ, Yoo HS · Pharmaceuticals
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.
pmc 2026
Kang X, Wang S, Zhang L, Hu M, Su X, Liu Y, Qin Q, Yi H, Yuan L, Cai W, Wei L, Lu Z · Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
pmc
Liu H, Qian SC, Zhang YY, Tang CB, Yue HH, Fan GL, Zhao X, Jiang YY, Huang FH, Zeng ZH, Wang W, Lu XR, Luo XK, Bai XF, Zheng XX, Xie P, Ma C, Zhao S, Zhang HJ, On the behalf of China Additive Anti-inflammatory...
Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.
pmc 2025
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z · Journal of gastroenterology and hepatology
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
pmc 2026
Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, Chang YL · Journal of the Chinese Medical Association : JCMA
Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
pmc 2020
Li T, Wu BL, Yu CL, Jin LY · Clinical case reports
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
pmc 2026
Shyanti RK, Sharma S, Haque M, Tiwari RK, Singh R, Mishra M · Discover oncology
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.
pmc
González JRA, Aparicio Osorio AAA, Coba IC, García JLA, López JA, Vargas RB, González MA · Open Forum Infectious Diseases
P-30. Thymosin-α1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patients.
pmc 2026
· SAGE Publications
{BLR 1548} SciClone - Alpha 1 Biomedical - Thymosin Alpha 1 - Arbitration
crossref 1993
Antoniya Hachmeryan, Negrin Negrev, Yuri Nyagolov · "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences
Hypocoagulability in Rats Induced by Thymic Peptides: Thymulin, Thymosin Alpha 1 and Thymosin Beta 4
crossref 2018
M.A. Elizondo-Riojas, D.G. Gorenstein, D.E. Volk · Worldwide Protein Data Bank
NMR structure of thymosin alpha-1
crossref 2011
Two peptides related to thymosin alpha 1 have been isolated from preparations of calf thymosin fraction 5. One, lacking four amino acid residues at the COOH terminus, is designated des-(25-28)-thymosin alpha 1. The other, named thymosin alpha 11, contains seven additional amino acid residues at...
Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5.
crossref 1983
· Oxford University Press (OUP)
Thymosin alpha-1
crossref 2001
· SAGE Publications
{BLR 2674} Hepatitis - Kuwait - SciClone - Thymosin
crossref 1998
R. King, C. Tuthill · Elsevier
Immune Modulation with Thymosin Alpha 1 Treatment
crossref 2016
· Elsevier BV
224 Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1 (TA1)
crossref 1993
A.A. Haritos, Gregory J. Goodall, B.L. Horecker · Proceedings of the National Academy of Sciences · 182 citations
Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.
openalex 1984
Su-Sun Wang, I. D. KULESHA, Donald P. Winter · Journal of the American Chemical Society · 91 citations
Synthesis of thymosin .alpha.1
openalex 1979
Asimina Dominari, Donald Hathaway, Krunal Balvantbhai Pandav, Wanessa F Matos, Sharmi Biswas, G. Narasimha Reddy et al. · World Journal of Virology · 70 citations
Thymosin alpha 1: A comprehensive review of the literature
openalex 2020
R. King, Cynthia W. Tuthill · Vitamins and hormones · 77 citations
Immune Modulation with Thymosin Alpha 1 Treatment
openalex 2016
Yueping Liu, Yue Pan, Zhenhong Hu, Ming Qing Wu, Chenhui Wang, Zeqing Feng et al. · Clinical Infectious Diseases · 169 citations
Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
openalex 2020
Enrico Garaci, Cartesio Favalli, Francesca Pica, Paola Sinibaldi Vallebona, Anna Teresa Palamara, Claudia Matteucci et al. · Annals of the New York Academy of Sciences · 47 citations
Thymosin Alpha 1
openalex 2007
Jianfeng Wu, Lixin Zhou, Jiyun Liu, Gang Ma, Qiuye Kou, Zhijie He et al. · Critical Care · 121 citations
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
openalex 2013
Cartesio Favalli, Teresa Jezzi, Antonio Mastino, C Rinaldi, Carlo Riccardi, Enrico Garaci · Cancer Immunology Immunotherapy · 63 citations
Modulation of natural killer activity by thymosin alpha 1 and interferon
openalex 1985
Connected data hub
Records with source provenance.
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Clinical Trial
20 recordsclinicaltrialsAdmin reviewed
Thymosin Alpha-1 for irAE Secondary to ICIs
Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related...
clinicaltrialsAdmin reviewed
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Primary Objective: To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma . Secondary Objective: To evaluate the safety and tolerability of adenpeptide-α1 combined with PD-1 antibody in elderly patients...
clinicaltrialsAdmin reviewed
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
clinicaltrialsAdmin reviewed
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
clinicaltrialsAutomated import
Thymosin-α1 for Recurrent Implantation Failure
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
clinicaltrialsAutomated import
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
The primary objective of this clinical trial is to evaluate the efficacy and safety of spatially fractionated radiotherapy combined with the PraG strategy in the treatment of soft tissue sarcoma (STS). The main questions it aims to answer...
clinicaltrialsAutomated import
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic...
clinicaltrialsAutomated import
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy...
clinicaltrialsAutomated import
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled, phase II clinical trial. The study aims to enroll 48 patients with resectable, locally advanced gastroesophageal junction adenocarcinoma who have not received any treatment. After obtaining informed consent and meeting the...
clinicaltrialsAutomated import
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
This is a multicenter, open-label, prospective, randomized controlled Phase II clinical study. All eligible subjects will be randomly assigned in a 1:1 ratio to either the triple therapy group or the double therapy group. Triple therapy group: Subjects...
clinicaltrialsAutomated import
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine chemotherapy + anti-PD-1 monoclonal antibody and Thymalfasin...
clinicaltrialsAutomated import
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to...
clinicaltrialsAutomated import
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
clinicaltrialsAutomated import
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with...
clinicaltrialsAutomated import
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic...
clinicaltrialsAutomated import
Abscopal Effect for Metastatic Small Cell Lung Cancer
Patients with small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect)...
clinicaltrialsAutomated import
Abscopal Effect for Metastatic Colorectal Cancer
Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy...
clinicaltrialsAutomated import
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.
clinicaltrialsAutomated import
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients. The final aim...
clinicaltrialsAutomated import
Dendritic Cell Based Therapy for Breast Cancer Patients
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha and interleukin-2. The secondary...
Open Access Article
8 recordspmcAutomated import
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.
Kim SD, Kim KR, Kim DH, Yeo T, Choi MJ, Park SJ, Yoo HS · Pharmaceuticals
pmcAutomated import
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z · Journal of gastroenterology and hepatology
pmcAutomated import
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
Li T, Wu BL, Yu CL, Jin LY · Clinical case reports
pmcAutomated import
P-30. Thymosin-α1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patients.
González JRA, Aparicio Osorio AAA, Coba IC, García JLA, López JA, Vargas RB, González MA · Open Forum Infectious Diseases
pmcAutomated import
Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.
Liu H, Qian SC, Zhang YY, Tang CB, Yue HH, Fan GL, Zhao X, Jiang YY, Huang FH, Zeng ZH, Wang W, Lu XR, Luo XK, Bai XF, Zheng XX, Xie P, Ma C, Zhao S, Zhang HJ,...
pmcAutomated import
Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, Chang YL · Journal of the Chinese Medical Association : JCMA
pmcAutomated import
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
Kang X, Wang S, Zhang L, Hu M, Su X, Liu Y, Qin Q, Yi H, Yuan L, Cai W, Wei L, Lu Z · Advanced science (Weinheim, Baden-Wurttemberg, Germany)
pmcAutomated import
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.
Shyanti RK, Sharma S, Haque M, Tiwari RK, Singh R, Mishra M · Discover oncology
Publication
9 recordspubmedAutomated import
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z
pubmedAutomated import
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
Mazza AD
pubmedAutomated import
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
Li T, Wu BL, Yu CL, Jin LY
pubmedAutomated import
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.
Kim SD, Kim KR, Kim DH, Yeo T, Choi MJ, Park SJ, Yoo HS
pubmedAutomated import
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
Kang X, Wang S, Zhang L, Hu M, Su X, Liu Y, Qin Q, Yi H, Yuan L, Cai W, Wei L, Lu Z
pubmedAutomated import
Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.
Chuang SC, Hung PC, Rethi L, Lin YW, Chau HD, Pham VK, Vo AT, Nguyen HT, Tzou KY, Chuang AE
pubmedAutomated import
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro.
Mishra S, Telang G, Sureshbabu A, Kulkarni S, Barage S, Kumar AWS, Singh R
pubmedAutomated import
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
Wei Y, Chen J, Zhang Y, Liu Y, Zhu F, Wang X, Zhou X, Wu C, Zhang W, Chen J, Zhang Y, Pan N, Chen K, Zheng S, Yan C, Liu L, Wang L
pubmedAutomated import
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.
Shyanti RK, Sharma S, Haque M, Tiwari RK, Singh R, Mishra M
Article
7 recordsopenalexAutomated import
Thymosin alpha 1: A comprehensive review of the literature
Asimina Dominari, Donald Hathaway, Krunal Balvantbhai Pandav, Wanessa F Matos, Sharmi Biswas, G. Narasimha Reddy et al. · World Journal of Virology · 70 citations
openalexAutomated import
Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
Yueping Liu, Yue Pan, Zhenhong Hu, Ming Qing Wu, Chenhui Wang, Zeqing Feng et al. · Clinical Infectious Diseases · 169 citations
openalexAutomated import
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Jianfeng Wu, Lixin Zhou, Jiyun Liu, Gang Ma, Qiuye Kou, Zhijie He et al. · Critical Care · 121 citations
openalexAutomated import
Thymosin Alpha 1
Enrico Garaci, Cartesio Favalli, Francesca Pica, Paola Sinibaldi Vallebona, Anna Teresa Palamara, Claudia Matteucci et al. · Annals of the New York Academy of Sciences · 47 citations
openalexAutomated import
Modulation of natural killer activity by thymosin alpha 1 and interferon
Cartesio Favalli, Teresa Jezzi, Antonio Mastino, C Rinaldi, Carlo Riccardi, Enrico Garaci · Cancer Immunology Immunotherapy · 63 citations
openalexAutomated import
Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.
A.A. Haritos, Gregory J. Goodall, B.L. Horecker · Proceedings of the National Academy of Sciences · 182 citations
openalexAutomated import
Synthesis of thymosin .alpha.1
Su-Sun Wang, I. D. KULESHA, Donald P. Winter · Journal of the American Chemical Society · 91 citations
Scholarly Work
8 recordscrossrefAutomated import
Hypocoagulability in Rats Induced by Thymic Peptides: Thymulin, Thymosin Alpha 1 and Thymosin Beta 4
Antoniya Hachmeryan, Negrin Negrev, Yuri Nyagolov · "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences
crossrefAutomated import
Immune Modulation with Thymosin Alpha 1 Treatment
R. King, C. Tuthill · Elsevier
crossrefAutomated import
NMR structure of thymosin alpha-1
M.A. Elizondo-Riojas, D.G. Gorenstein, D.E. Volk · Worldwide Protein Data Bank
crossrefAutomated import
Thymosin alpha-1
· Oxford University Press (OUP)
crossrefAutomated import
{BLR 2674} Hepatitis - Kuwait - SciClone - Thymosin
· SAGE Publications
crossrefAutomated import
{BLR 1548} SciClone - Alpha 1 Biomedical - Thymosin Alpha 1 - Arbitration
· SAGE Publications
crossrefAutomated import
224 Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1 (TA1)
· Elsevier BV
crossrefAutomated import
Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5.
Two peptides related to thymosin alpha 1 have been isolated from preparations of calf thymosin fraction 5. One, lacking four amino acid residues at the COOH terminus, is designated des-(25-28)-thymosin alpha 1. The other, named thymosin alpha 11,...
Book-chapter
1 recordsopenalexAutomated import
Immune Modulation with Thymosin Alpha 1 Treatment
R. King, Cynthia W. Tuthill · Vitamins and hormones · 77 citations
Live discovery
Latest research signals
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Recent PubMed records
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.PMID 42797537 · 2026 Sep 19Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.PMID 42693587 · 2026 Sep 3Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.PMID 42641753 · 2026 Oct 28Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro.PMID 42345155 · 2026 Jun 1Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.PMID 42295795 · 2026 Sep 2Registered clinical studies
A Trial of Thymalfasin in Adult Patients With Hepatocellular CarcinomaNCT00082082 · COMPLETEDProtective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)NCT06966687 · ENROLLING_BY_INVITATIONStudy of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung CancerNCT03659578 · COMPLETEDResponsible use of information
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.